These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 2878748

  • 1. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [Abstract] [Full Text] [Related]

  • 2. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A.
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [Abstract] [Full Text] [Related]

  • 3. Somatostatin analog treatment of acromegaly: new aspects.
    Lamberts SW, del Pozo E.
    Horm Res; 1988 Aug; 29(2-3):115-7. PubMed ID: 2900190
    [Abstract] [Full Text] [Related]

  • 4. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 5. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ, Harris AG, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
    Lamberts SW, Verleun T, Zuiderwijk JM, Oosterom R.
    Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Jan; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 12. A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo.
    Lamberts SW, van Koetsveld P, Hofland L.
    Clin Endocrinol (Oxf); 1989 Oct; 31(4):401-10. PubMed ID: 2627746
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S.
    J Clin Invest; 1997 Nov 01; 100(9):2386-92. PubMed ID: 9410919
    [Abstract] [Full Text] [Related]

  • 14. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
    Horikawa R, Takano K, Hizuka N, Asakawa K, Shibasaki T, Masuda A, Shizume K.
    Endocrinol Jpn; 1986 Dec 01; 33(6):743-9. PubMed ID: 2884093
    [Abstract] [Full Text] [Related]

  • 15. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a.
    Lamberts SW, Reubi JC, Uiterlinden P, Zuiderwijk J, van den Werff P, van Hal P.
    Endocrinology; 1986 Jun 01; 118(6):2188-94. PubMed ID: 2870915
    [Abstract] [Full Text] [Related]

  • 16. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
    Chang CC, Chen FW, Hsieh HC.
    Taiwan Yi Xue Hui Za Zhi; 1989 May 01; 88(5):443-9. PubMed ID: 2507734
    [Abstract] [Full Text] [Related]

  • 17. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E.
    Lancet; 1984 Oct 06; 2(8406):782-4. PubMed ID: 6148524
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects.
    Losa M, Schopohl J, Müller OA, von Werder K.
    Acta Endocrinol (Copenh); 1985 Aug 06; 109(4):467-73. PubMed ID: 3929513
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion.
    Serri O.
    Clin Endocrinol (Oxf); 1987 Dec 06; 27(6):675-82. PubMed ID: 2901301
    [Abstract] [Full Text] [Related]

  • 20. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ.
    J Clin Endocrinol Metab; 1985 Jun 06; 60(6):1148-53. PubMed ID: 3923021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.